Carina Biotech

Carina Biotech is an Australian clinical-stage immunotherapy company focused on developing chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. The company utilizes proprietary technology platforms to engineer CAR-T cells that target atypical solid cancer antigens, aiming to improve therapy precision and reduce off-target effects. Their research includes a Multifunctional Chemokine Receptor Platform, which enhances the ability of CAR-T cells to actively migrate to and infiltrate solid tumors, as well as specialized manufacturing processes designed to produce high-potency cells with lower rates of exhaustion.

These advancements address critical challenges in solid tumor treatment, such as the scarcity of effective target antigens, limited tumor accessibility, and the immunosuppressive nature of the tumor microenvironment. The company's lead program targets LGR5, a cancer stem cell marker associated with advanced colorectal cancer, and has demonstrated the potential for complete tumor regression in preclinical models. By targeting cancer stem cells, Carina seeks to achieve durable tumor suppression and prevent cancer recurrence, addressing significant unmet needs for patients with difficult-to-treat solid malignancies.